Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Viola W. Zhu"'
Autor:
Michael Duruisseaux, Philippe Brun, Valérie Gounant, Alison M. Schram, Maria E. Arcila, Yonina R. Murciano-Goroff, Miguel Angel Molina, Masaoki Ito, Morihito Okada, Joshua K. Sabari, Denis Moro-Sibilot, Clarisse Dupont, Christina Falcon, Lucia Anna Muscarella, Alexa B. Schrock, Torsten Blum, Alexander Drilon, Marie Wislez, Robert C. Doebele, Haiquan Chen, Eva Brandén, Siraj M. Ali, Fanny Magne, Misako Nagasaka, D. Ross Camidge, Sai-Hong Ignatius Ou, Giulio Rossi, Jin-Yuan Shih, Viola W. Zhu, Jacques Cadranel, Soo-Ryum Yang, Maurice Pérol, Isabelle Monnet, Stephen V. Liu, Rafael Rosell, Ji Youn Han
Publikováno v:
Journal of Clinical Oncology. 39:2791-2802
PURPOSEAlthough NRG1 fusions are oncogenic drivers across multiple tumor types including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 registry was thus established to characterize NRG1 fusion–positive lung c
Autor:
Sai-Hong Ignatius Ou, Yanfei Gao, Viola W. Zhu, Kenneth A. Bauer, Joseph J. Zhao, Nicholas Syn, Shannon S. Zhang, Misako Nagasaka
Publikováno v:
Lung Cancer. 157:147-155
INTRODUCTION Increased thromboembolism (TE) has been reported in ALK+ and ROS1+ non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Odds ratios (OR) and hazard ratios (HR) of TE were calculated from meta-analysis and time-to-event analysis resp
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Steven Zhang, Daniel B. Costa, Gregory J. Riely, Viola W. Zhu, Howard West, Shuanglian Li, Pasi A. Jänne, Alexander I. Spira, Tarek Mekhail, Sylvie Vincent, Joel W. Neal, Jyoti D. Patel, Lyudmila Bazhenova, Shirish M. Gadgeel, Zofia Piotrowska, Veronica Bunn, D. Ross Camidge, Jianchang Lin, S. Jin, Anne S. Tsao, Ryan D. Gentzler, Danny Nguyen
Publikováno v:
Cancer Discovery. 11:1688-1699
Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR gene mutations, including exon 20 insertions (EGFRex20ins), in non–small cell lung cancer, was evaluated in a phase I/II dose-escalation/expansion trial (Clinica
Autor:
Alexis B. Cortot, Sébastien Couraud, M. van den Heuvel, Julie Milia, Benjamin Besse, S-H.I. Ou, Sacha I. Rothschild, Mickaël Lattuca-Truc, Laura Mezquita, Joel W. Neal, Rafael Rosell, Amélie Lusque, R.D. Schouten, Terry L. Ng, Martin Früh, Marcel Wiesweg, Benjamin Solomon, D.R. Camidge, Nir Peled, C. Mascaux, Gérard Zalcman, Alexander Drilon, Alessandra Curioni-Fontecedro, Heather A. Wakelee, Alex Martinez-Marti, Paolo Bironzo, Julien Mazieres, Sanjay Popat, Valérie Gounant, Laurent Mhanna, Remi Veillon, Viola W. Zhu, Oliver Gautschi, Fabrice Barlesi, Joshua K. Sabari, Silvia Novello, A. Thai, Joachim Diebold
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2019, 30 (8), pp.1321-1328. ⟨10.1093/annonc/mdz167⟩
Annals of oncology : official journal of the European Society for Medical Oncology, vol 30, iss 8
Annals of Oncology, 30, 8, pp. 1321-1328
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Annals of Oncology, 30, 1321-1328
Annals of Oncology, 2019, 30 (8), pp.1321-1328. ⟨10.1093/annonc/mdz167⟩
Translational Cancer Research
Annals of Oncology, Elsevier, 2019, 30 (8), pp.1321-1328. ⟨10.1093/annonc/mdz167⟩
Annals of oncology : official journal of the European Society for Medical Oncology, vol 30, iss 8
Annals of Oncology, 30, 8, pp. 1321-1328
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Annals of Oncology, 30, 1321-1328
Annals of Oncology, 2019, 30 (8), pp.1321-1328. ⟨10.1093/annonc/mdz167⟩
Translational Cancer Research
Contains fulltext : 215810.pdf (Publisher’s version ) (Closed access) BACKGROUND: Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI acr
Autor:
Kumar Abhishek, Sherri Z. Millis, Venkataprasanth P. Reddy, Katherine A. Janeway, Jeffrey S. Ross, Breelyn A. Wilky, Phil Stephens, Ethan Sokol, Umut Disel, Mehmet Akif Ozturk, Alexa B. Schrock, Sumanta K. Pal, Viola W. Zhu, Mrinal M. Gounder, Sai-Hong Ignatius Ou, Samuel J. Klempner, Chaitali Singh Nangia, Ruben Cabanillas, Vincent A. Miller, Nuri Karadurmus, Jennifer Webster, Jon Chung, Christine M. Lovly, Shridar Ganesan, Lee A. Albacker, Salil Soman, Asli O. Matos, Adam Benson, Garrett M. Frampton, Sally E. Trabucco, Russell Madison, Siraj M. Ali, Semra Paydas
Publikováno v:
The oncologist, vol 25, iss 1
The Oncologist
The Oncologist
Purpose Amplifications of receptor tyrosine kinases (RTKS) are therapeutic targets in multiple tumor types (e.g. HER2 in breast cancer), and amplification of the chromosome 4 segment harboring the three RTKs KIT, PDGFRA, and KDR (4q12amp) may be simi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 158
Since the discovery of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) gene fusion in non-small cell lung carcinoma (NSCLC) in 2007, more than 10 EML4-ALK variants based on the exon breakpoints in EML4 hav
Autor:
Viola W. Zhu, Sai-Hong Ignatius Ou
Publikováno v:
Lung Cancer. 130:201-207
The incidence of CNS metastasis at the time of diagnosis of and during the natural disease history of advanced ROS1+ NSCLC is largely unknown. It is generally believed that the incidence of CNS metastasis is lower in ROS1+ NSCLC than ALK+ NSCLC as RO
Autor:
Alice T. Shaw, Jochen K. Lennerz, Mari Mino-Kenudson, Hideko Isozaki, Subba R. Digumarthy, Inga T. Lennes, Rebecca J. Nagy, Corinne Clifford, Aaron N. Hata, Jessica J. Lin, Lecia V. Sequist, Mandeep Banwait, Amanda K. Riley, Dora Dias-Santagata, Justin F. Gainor, Zofia Piotrowska, Sai-Hong Ignatius Ou, Varuna Nangia, Viola W. Zhu, Rebecca S. Heist, Richard B. Lanman, Nicolas Marcoux, Wenjia Su, A. John Iafrate, Satoshi Yoda, Erica Evans, Beni B. Wolf
Publikováno v:
Cancer Discovery. 8:1529-1539
We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired CCDC6–RET fusion. Although RET fusions have been identified in resistant EGFR-mutant non–small cell lung cancer (NSCLC), their role in acquired
Autor:
Eric B. Haura, A. John Iafrate, Alexander Drilon, Alexander I. Spira, Shivaani Kummar, Sai-Hong Ignatius Ou, Martin S. Taylor, Long P. Le, Viola W. Zhu, Jochen K. Lennerz, Mari Mino-Kenudson, Ryma Benayed, Maria E. Arcila, Theresa A. Boyle, Robert C. Doebele, Anna F. Farago, Alice T. Shaw, Nora Horick, Dara L. Aisner
Publikováno v:
JCO Precision Oncology. :1-12
Purpose Gene rearrangements that involve NTRK1/2/3 can generate fusion oncoproteins that contain the kinase domains of TRKA/B/C, respectively. These fusions are rare in non–small-cell lung cancer (NSCLC), with frequency previously estimated to be <